CD19 and Miyoshi myopathy: We utilized TMT-based proteomics with a booster channel to identify proteins specific to MM cells compared with hematopoietic stem and progenitor cells (CD34+), B cells (CD19+) and plasma cells (CD138+) isolated from the bone marrow of healthy donors (Fig. 6a).